Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

@article{Churchyard1997AutonomicEO,
  title={Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.},
  author={Andrew C Churchyard and Christopher J. Mathias and P Boonkongchuen and A. J. Lees},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={1997},
  volume={63 2},
  pages={228-34}
}
OBJECTIVES The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease randomised to receive selegiline (10 mg/day) and levodopa compared with those taking levodopa alone. Unwanted effects of selegiline on cardiovascular regulation have been investigated as a potential cause for the unexpected mortality finding of the UKPDRG trial. METHODS The cardiovascular responses to a range of physiological stimuli, including… CONTINUE READING